Loading…

Loading grant details…

Completed HORIZON European Commission

Next generation toolbox for greener pharmaceuticals design & manufacturing towards reduced environmental impact

€7.52M EUR

Funder European Commission
Recipient Organization Risa Sicherheitsanalysen Gmbh
Country Germany
Start Date Jun 01, 2022
End Date Nov 30, 2025
Duration 1,278 days
Number of Grantees 18
Roles Participant; Coordinator; Associated Partner
Data Source European Commission
Grant ID 101057844
Grant Description

Pharmaceuticals have undoubtably made our world a better place, ensuring longer and healthier lives. However, pharmaceuticals and their active metabolites are rapidly emerging environmental toxicants.

It is thus critical that we fully understand, and mitigate where nec-essary, the environmental impact resulting from their production, use and disposal.

In this direction, ENVIROMED addresses two aspects of the environmental impact of pharmaceuticals, a) impact of the processes in manufacturing the compound, and b) impact of the compound itself, during its lifecycle.

The project narrows the knowledge gap when it comes to the effect of pharmaceutical compounds, and their derivatives, in the environment as it enables the better understanding the environmental impact of such compounds, throughout their lifecycle.

It aims to offer (via extensive monitoring campaigns & scientific studies) information regarding occurrence of pharmaceuticals in the environment, their persistence, environmental fate, and toxicity (via in-vitro & in-vivo models) as well as application of in-silico methods to provide information about the basic risk management and fate prediction in the environment.

Brief ideas about toxicity endpoints, available ecotoxicity databases, and expert systems employed for rapid toxicity predictions of ecotoxicity of pharmaceuticals will also be taken into account, in order to have a comprehensive approach to pharmaceuticals' Lifecycle Assessment (LCA).

Moreover, the project aims at developing a set of technologies that enable greener and overall, more efficient pharmaceuticals production, which include: a) Green-by-design in-silico drug development; b) Novel sensing to allow reduction of rinsing chemicals and cycles; c) a robust Continuous Biomanufacturing line (CBM), which makes use of AI-enabled process optimisation and prediction, using data assimilation based on chemical sensing and energy disaggregation/monitoring.

Training activities and a robust exploitation

All Grantees

Mitera Idiotiki Geniki, Maieytiki,Gynaikologiki Kai Paidiatriki Kliniki Anonymi Etaireia; Technische Universitaet Wien; Uab Metis Baltic; Risa Sicherheitsanalysen Gmbh; Universitaet Ulm; Ethnicon Metsovion Polytechnion; Pfizer Ireland Pharmaceuticals; Cloudpharm Private Company; Innovation in Research & Engineering Solutions; Fraunhofer Uk Research Limited; Consiglio Nazionale Delle Ricerche; Horiba Europe Gmbh; Etaireia Ydreyseos Kai Apochetefseos Proteyoysis Anonimi Etaireia; Alpes Lasers Sa; Research Center for Non Destructive Testing Gmbh; Novo Nordisk A/S; Cy.R.I.C Cyprus Research and Innovation Center Ltd; Plegma Labs Technologikes Lyseis Anonymos Etairia

Advertisement
Apply for grants with GrantFunds
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant